For instance, Cetuximab, a chimeric immunoglobulin G2 monoclonal antibody that binds specifically to EGFR and competitively inhibits the binding of EGF and other ligands [27], has been developed to be used in patients with different cancers with high expression of EGFR including cervical cancers. This evidence concerns the gene EGFR and cancer.